SCHEMBL18220004

SCHEMBL18220004

COCCNS(=O)(=O)/C(C#N)=C(\C)c1ccc2cc(N3CCCCC3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.47
MAPT P10636 7/20 0.38
ALDH1A1 P00352 6/20 0.38
GAA P10253 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
SLC16A3 O15427 2/20 0.37
SLC16A1 P53985 2/20 0.37
KMT2A Q03164 6/20 0.37
MEN1 O00255 4/20 0.37
KDM4E B2RXH2 2/20 0.37
ALOX15 P16050 2/20 0.37
TSHR P16473 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
MCL1 Q07820 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17595280 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL29949957 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL17595282 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL17595523 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL17595281 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL18220453 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL29663165 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL17595524 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL17595525 0.95 APP (0.53) APPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL18220008 0.92 APP (0.48) APPMAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885MAPT 25/4885ALDH1A1 4151/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885MAPT 25/4885ALDH1A1 4151/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885MAPT 25/4885ALDH1A1 4151/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885MAPT 26/4885ALDH1A1 4226/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885MAPT 25/4885ALDH1A1 4151/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885MAPT 26/4885ALDH1A1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.